Latest Latin America News

Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.

Piche Resources announces the resignation of Managing Director Karilyn Farmer effective April 2026, with seasoned geologist Claudio Devaux appointed as country manager to ensure continuity in exploration activities.

Brambles Limited reported a 5% rise in sales revenue and a 7% increase in underlying profit for the half-year ended December 2025, alongside a raised interim dividend. The company navigated volume declines with price realisation and productivity gains, while advancing sustainability goals.

Lycopodium Limited reports strong half-year results for 1H FY26, driven by increased project delivery and strategic expansion into the Americas. The company updates its full-year guidance amid a robust pipeline across gold, copper, and critical minerals.

Osteopore Limited has secured an exclusive three-year distribution deal with Medprin Biotech GmbH to broaden its presence in Latin America's craniofacial reconstruction market, tapping into a region poised for significant growth.

CAR Group Limited has reported a strong first half for FY26, posting 13% revenue growth and reaffirming its optimistic outlook for the full year, driven by strategic AI integration and global market expansion.

CAR Group has reported strong first-half results for FY26, with double-digit revenue and earnings growth across all key regions, underpinned by strategic AI investments and expanding market presence.

CAR Group Limited reported a strong half-year result for the period ending 31 December 2025, with revenue up 8% and adjusted net profit rising 11.5%, driven by robust performance across Australia, North America, Latin America, and Asia.

ResMed Inc. reported robust financial results for Q2 FY2026, driven by strong demand in its Sleep and Breathing Health and Residential Care Software segments. The company also navigates ongoing patent litigation while maintaining solid liquidity and shareholder returns.

Ava Risk Group reports a softer first half with delayed orders impacting revenue, but anticipates a robust recovery in the second half backed by new contracts and a strategic investment.

Resmed Inc. posted robust Q2 FY2026 results, with revenue climbing 11% to $1.4 billion and a 16% rise in non-GAAP earnings per share, underpinned by strong global demand and operational efficiencies.

Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.